ScreenerHero

LTRNLantern Pharma Inc.

NAS · US · Healthcare · Biotechnology · lanternpharma.com
2.340USD-6.02%Mkt Cap: 29.91M $P/E: —

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small ce…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap29.91M $
Enterprise Value23.69M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-17.12M $
Revenue/Share—
Last Price2.340 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.13
PEG—
EV/EBITDA-1.43
EV/Revenue—
P/S—
P/B7.48
EPS (TTM)-1.51
EPS (Forward)-2.02
52W Range
1.11034% of range4.750
52W High4.750 USD
52W Low1.110 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-262.00%
ROA-155.13%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.68M $
CapEx (TTM)1.72K $
FCF Margin—
FCF Yield-30.05%
Net Debt-6.26M $
Net Debt/EBITDA0.38
Balance Sheet
Debt/Equity0.01
Current Ratio1.87
Quick Ratio1.68
Book Value/Sh0.3060 USD
Cash/Share0.5590 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.50 USD
Upside (mean)+647.9%
Target Range10.00 USD – 25.00 USD
$10.00+647.9% to mean$25.00
# Analysts2
Ownership
Shares Out.12.78M
Float8.70M
Insiders20.32%
Institutions24.92%
Short Interest
Short Ratio6.5d
Short % Float6.66%
Short % Out.6.63%
Shares Short846.37K
Short (prev mo.)929.05K
Technical
SMA 503.205 (-27.0%)
SMA 2003.002 (-22.1%)
Beta2.33
S&P 52W Chg18.16%
Avg Vol (30d)109.80K
Avg Vol (10d)116.48K
Technical Indicators
RSI (14)29.8
MACD-0.1744
MACD Signal-0.1692
MACD Hist.-0.0051
BB Upper2.948 USD
BB Middle2.678 USD
BB Lower2.408 USD
BB Width20.19%
ATR (14)0.2511 USD
Vol Ratio (20d)2.23x